This trial was performed in three experienced centres in the United
States, namely, Nashville, TN; Philadelphia, PA; and San Francisco, CA. Following publication of this landmark trial, there was a rapid increase in the number of centres offering fetal surgery for myelomeningocele (MMC) worldwide. In the United States, a survey of 59 fetal care centres conducted in 2014 2 showed that nine centres were offering this service. As the response rate was under 50%, this is likely to have been an underestimate.
In Western Europe, fetal surgery for MMC was more slowly established. In the pre-MOMS era, the physician's attitude to open fetal surgery, mainly due to its maternal invasiveness, was suggested to be a limiting factor. 3, 4 Variation in the availability and uptake of pregnancy termination may also play a role in the perceived need for fetal MMC repair. 5 A study in Belgium and Holland in 2014, 6 found that over three quarters of patients diagnosed with fetal MMC opted to end the pregnancy. On the other hand, fetal surgery for MMC was more rapidly embraced 7 in some parts of Eastern Europe and South America where termination of pregnancy is less of an option, with several South American and one
Polish centre offering open fetal surgery for MMC pre-MOMS. 1, 8 Following its publication, an American College of Obstetricians and Gynecologists Committee Opinion 9 stated that the outcomes of the MOMS trial were likely to be the "best-case scenario" as the trial 
| METHODS
Through the International Society for Prenatal Diagnosis (ISPD) 15 Fetal Therapy Special Interest Group and NAFTNet, 16 fetal therapy centres offering fetal MMC repair or in preparation for offering this surgery were contacted from September 2017 to June 2018.
Centres were asked to provide the following information via email questionnaire:
• Is fetal surgery for MMC available in your centre/country?
• Who are the lead clinicians for this service?
• Where do your patients come from?
• What criteria do you use when offering surgery?
• What access method is offered (open or fetoscopic)?
• What exact neurosurgical repair techniques are used?
• What is the estimated number of cases performed to date?
• Has your outcome data been published or presented?
or any other comments.
The responses were analysed, and an interactive map listing all the responding centres was published on the ISPD Fetal Therapy Special Interest Group website. 17 No ethical approval was required for this study as no primary patient data was collected.
3 | RESULTS
| Centres offering fetal surgery
Fifty-nine fetal therapy centres were identified as potentially offering fetal MMC surgery (Figure 1 ), of which contact details were available for 56 centres. Responses were received from 44 centres (74.6%).
Three centres (6.8%) did not have a fetal surgery service and were excluded from further analysis. Thirty-four centres (77.3%) were performing fetal surgery for MMC, and seven centres (15.9%) had set up a fetal surgery service but were still awaiting a first case ( 
| Patient criteria
Most centres reported following the MOMS trial inclusion criteria, • Provision of fetal surgery has expanded since the MOMS trial, but it is unclear how many centres offer fetal MMC closure.
• Various closure techniques have been described, particularly for fetoscopic surgery.
• Case series suggest a broadening of inclusion criteria from those used in the MOMS trial.
What does this study add?
• This study provides a global resource of centres offering fetal surgery for MMC and details of their service.
• Two thirds of centres perform this operation by hysterotomy and the vast majority with patient inclusion criteria based on the level 1 RCT evidence (the MOMS trial).
• A few centres now offer surgery up to 28 weeks of gestation, beyond the MOMS trial inclusion criteria.
• Joana/EPM-UNIFESP-São Paulo, Brazil).
• One centre reported offering fetal surgery up to a BMI of 45 if the placenta was posterior (German Center for Fetal Surgery and Minimally Invasive Therapy, Mannheim).
• A relaxation of the minimum age restriction (18 years in MOMS) and the requirement for US citizenship or residency was reported by two US centres.
• One centre reported that fetal kyphosis greater then 30°and a short cervix were not used as exclusion criteria (Hospital Albert Einstein, Sao Paulo). Although entry and closure techniques of the hysterotomy were not specifically enquired about, four centres reported using a different uterine entry technique to the auto-stapling device (US Surgical CS-57, Covidien, USA) described in MOMS, in order to perform a 6 to 8-cm hysterotomy. 18, 19 Two centres reported using a "mini" (less than 4 cm) rather than a wide hysterotomy for uterine access. One centre reported a modified hysterotomy closure technique, using three rather than two layers. 
| Type of fetal surgery offered

| Access and neurosurgical technique of fetal surgery by hysterotomy
| Access and neurosurgical technique of fetoscopic surgery
Fifteen centres performing or planning to perform fetoscopic MMC repair were identified. Of these, 11 were already performing fetoscopic surgery (five fetoscopic only, six alongside open surgery), and four centres were setting up fetoscopic surgery (two fetoscopic only, two alongside open surgery). All centres reported using or planning to use partial amniotic carbon dioxide insufflation. 21 There was variation in uterine access and operative techniques between centres ( Table 2 ). The main fetal neurosurgical repair techniques identified so far are illustrated in Figure 4 .
| Number of cases
The Table 3 ). A few centres reported performing relatively large numbers of cases, whereas many centres reported performing relatively few cases, resulting in a higher-mean number of cases per centre than median.
| Outcome data
All North American centres reported submitting their outcome data to the NAFTNet registry. Three US centres also reported publication of their results in peer-reviewed journals, [22] [23] [24] as did five centres outside North America. Group map, 17 which may have influenced responses. Finally, whilst "outcome data" was enquired about, particular parameters such as gestational age at delivery, shunt rate, or mobility, were not requested.
The majority of fetal therapy centres were either contributing to a database of outcomes, publishing and presenting outcomes, or planning to do so. However, with the exception of NAFTNet, there is no cross-centre collection of data that could be used for pooling outcomes and furthering knowledge. To this end, the option of a global database could be considered in the future. 
